Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Learn the key factors to inspect when comparing funds, including costs, performance, and risk, to make informed investment choices.
18,813 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A fresh take on dine brands (din) 2025, focusing on Q4 signals, brand momentum, and how investors can position themse...
A veteran financial journalist breaks down abacus global (abx) 2025 Q4 results, explains what the numbers mean for 20...
Two ad-tech leaders with different business models, The Trade Desk and AppLovin, reveal distinct quarterly revenue pa...
Realtor.com launches AGOYU AI-powered moving quotes, letting users generate real-time estimates from video without in...
Inflation has squeezed most Americans, but American Express remains focused on the affluent. This article examines wh...
Rising electricity costs driven by AI data centers are reshaping the landscape for utility stocks. This deep dive exp...
As travel rebounds, premium demand is reshaping cruise stock dashboards. This deep dive explains why norwegian cruise...
Mission Produce enters 2026 with a mix of hedges, growing demand, and a tight supply chain. This guide breaks down wh...
Investors eyeing mdxhealth (mdxh) 2026 earnings will focus on adoption rates, reimbursement, and partnerships. This g...
Insider activity can be a clue about a company’s path, but the motives are varied. This article dissects iradimed's s...
June brought a tech-focused pullback as Apple raised device prices to offset memory costs. This deep dive explains wh...